Merck & Co., Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. April 14, 2025 Deadline to file Lead Plaintiff Motion

Core Viewpoint - Merck & Co., Inc. is facing a class action lawsuit from investors who purchased securities during the specified class period, primarily due to the company's failure to meet projected revenue from Gardasil sales by 2030 [1][4]. Group 1: Class Action Details - The class action represents investors who bought Merck securities between February 3, 2022, and February 3, 2025, with a deadline of April 14, 2025, for filing a lead plaintiff motion [1]. - Investors are encouraged to contact the Portnoy Law Firm for legal rights discussions and complimentary case evaluations [2]. Group 2: Revenue Projections and Company Statements - The complaint highlights that Merck projected $11 billion in revenue from Gardasil sales by 2030, supported by optimistic statements regarding consumer demand and education efforts [3]. - The company had expressed confidence in driving demand for Gardasil, particularly in China, through targeted vaccination efforts [3]. Group 3: Stock Price Impact - On February 4, 2025, Merck announced it would not meet its Gardasil sales forecast, leading to a significant stock price drop from$99.79 to $90.74 per share, a decline of over 9% in one day [4]. - The announcement included a halt in Gardasil shipments to China to reduce inventory, attributing the decision to lower-than-expected demand [4].